Tag: suicide prevention

  • 🧠 Blog Post: The Dark Mirror—How Screen Time Drains Our Mental Health

    🧠 Blog Post: The Dark Mirror—How Screen Time Drains Our Mental Health

    It’s no secret that screen time affects our mental health—but we still underestimate just how deeply it cuts.

    As a psychiatrist, I find myself glued to my phone far more than I’d like. I’m not scrolling TikTok—I’m answering emails, responding to messages, and compulsively checking patient updates. Yet, even in this “productive” digital use, I feel drained. The compulsion to keep checking leaves me feeling hollow and anxious.

    Now imagine that same digital pull in the hands of a developing mind.

    A recent study in JAMA examined over 4285 adolescents and found a clear link: teens with high levels of addictive digital media use were significantly more likely to report depression, anxiety, and suicidal thoughts.

    The connection isn’t surprising. Much of what’s consumed online isn’t educational or uplifting—it’s filtered perfection, highlight reels, and influencer fantasy. The more time spent scrolling, the easier it is to feel like you’re falling behind in life, socially or emotionally.

    It’s telling that Steve Jobs famously limited his own children’s access to screens, despite pioneering the very technology we now feel chained to.

    This isn’t about demonizing devices—it’s about reclaiming our attention and protecting mental space, especially for young people.

    We need digital hygiene just like we need physical hygiene. That means:

    • Setting screen-time boundaries
    • Promoting offline connection
    • Reframing how we compare ourselves to curated content

    Mental health isn’t just shaped in the therapy room—it’s shaped by the world we scroll through every day.

  • Suicide is a tragically common outcome in schizophrenia

    🔹 Up to 50% of patients attempt suicide
    🔹 Around 10% die by suicide

    The InterSePT trial directly addressed this crisis by comparing clozapine vs olanzapine in high-risk patients—all with recent suicidal ideation or attempts. Notably, only 27% were treatment-resistant.

    ✅ Clozapine led to a 25% reduction in suicidal behaviors—a game-changer.
    📌 This led to FDA approval for clozapine in reducing suicidality in schizophrenia.

    Let’s stop thinking of clozapine only as a last resort. Sometimes, it’s exactly what’s needed—not later, but now.

  • The Importance of Distinguishing Suicidal Behaviors

    The Importance of Distinguishing Suicidal Behaviors

    This is the subject of a recent discussion I had with a colleague regarding the differences between a suicide attempt and a suicide gesture. Though these terms are sometimes used interchangeably in casual conversation or even in clinical documentation, they carry fundamentally different meanings—both in terms of patient risk and in how we, as clinicians, should respond.

    Our conversation emerged from a case involving a patient with borderline personality disorder who presented to the emergency department after ingesting a small quantity of over-the-counter medication. The intent was unclear. Was this a serious attempt to end her life? Or was it a gesture—an act of desperation without the intention to die, but rather to communicate emotional distress?

    The question is not academic. Our interpretation of the event determines our risk formulation, our documentation, our treatment planning, and even how we communicate with the patient and their support system. Yet, it is precisely in these gray areas that clinicians often struggle, and where outdated or stigmatizing language can do real harm.

    Defining the Terms: Clinical and Functional Differences

    suicide attempt refers to an act of self-harm with at least some intent to die. The degree of lethality may vary, but what distinguishes an attempt is that the individual believed the act could result in death and engaged in it with that goal in mind—even if ambivalence was present. The National Institute of Mental Health (NIMH) and the Columbia-Suicide Severity Rating Scale (C-SSRS) define this with some specificity: any potentially self-injurious behavior with non-zerointent to die, regardless of outcome.

    In contrast, a suicidal gesture is a behavior that mimics suicidal behavior or appears life-threatening but is typically not intended to be fatal. The function is often communicative or affect-regulating rather than aimed at death. Classic examples include superficial wrist-cutting, ingesting a sub-lethal dose of medication, or tying a noose but not tightening it. These acts often occur in interpersonal contexts and can be seen as efforts to signal pain, elicit help, or assert control in the face of perceived abandonment.

    Why the Distinction Matters

    It might be tempting to dismiss suicidal gestures as “attention-seeking” or “manipulative,” but this framing is both clinically dangerous and ethically fraught. Individuals who engage in gestures often experience intense psychological suffering, and repeated gestures are a well-established risk factor for future suicide attempts and completed suicide.

    From a risk assessment standpoint, gestures should be taken seriously, especially when they become part of a pattern. While the intent to die may not be present in a given gesture, intent can shift quickly, particularly in individuals with mood disorders, personality pathology, or under the influence of substances.

    From a treatment perspective, understanding the function of the behavior—whether it is to relieve affective tension, to communicate distress, or to punish oneself—is crucial to tailoring interventions. For instance, dialectical behavior therapy (DBT) explicitly targets self-harm and suicidal gestures as part of its hierarchy of treatment priorities, recognizing the urgency and potential danger of these behaviors even when lethality is low.

    Conclusion: Clarify, Don’t Categorize

    Ultimately, the conversation with my colleague reminded me that the real clinical challenge is not to label a behavior as a suicide attempt or a gesture, but to understand its meaning in the life of the patient. Both require empathy, structure, and a willingness to engage with complexity. Whether a patient wants to die or wants their suffering to be seen and acknowledged, both deserve serious clinical attention.

    By sharpening our definitions and approaching these behaviors with nuance, we can better serve patients in crisis and avoid the pitfalls of assumptions—especially in emotionally charged clinical environments like emergency rooms, inpatient units, or high-acuity outpatient settings.

  • EMA Warns of Suicidal Ideation from Finasteride

    EMA Warns of Suicidal Ideation from Finasteride

    In a significant update to its safety guidance, the European Medicines Agency (EMA) has officially recognized suicidal ideation as a potential side effect of finasteride. The EMA is urging healthcare professionals to advise patients to stop treatment and seek medical help if they experience depressed mood, depression, or suicidal thoughts while taking the drug.

    This decision follows a growing number of reports linking finasteride, particularly in younger men using it for androgenic alopecia (male pattern baldness), to neuropsychiatric side effects. While previous warnings have addressed sexual dysfunction, this marks a critical shift in regulatory focus to mental health.

    💊 What Is Finasteride?

    Finasteride is a 5α-reductase inhibitor used to treat:

    • Benign prostatic hyperplasia (BPH) in a 5 mg daily dose (Proscar)
    • Male pattern baldness (androgenic alopecia) in a 1 mg daily dose (Propecia)

    It works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT)—a potent androgen implicated in hair loss and prostate growth.

    ⚠️ The EMA’s Updated Warning

    The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) reviewed post-marketing surveillance data and published literature and concluded that:

    “There is sufficient evidence to support a causal relationship between finasteride and the risk of suicidal ideation.”

    Key recommendations:

    • Suicidal ideation will be added to the drug’s product information as a potential adverse effect.
    • Healthcare professionals should proactively inform patients about this risk.
    • Patients should be advised to discontinue treatment immediately and seek medical advice if they experience changes in mood or mental health.

    🧠 Possible Mechanisms Behind Finasteride’s Psychiatric Effects

    The exact mechanisms linking finasteride to depression and suicidality remain unclear, but several biological hypotheseshave been proposed:

    1. Neurosteroid Depletion

    Finasteride inhibits 5α-reductase, which not only converts testosterone to DHT but also helps produce neurosteroids like allopregnanolone and tetrahydrodeoxycorticosterone (THDOC).

    • These neurosteroids have potent GABAergic activity, contributing to anxiolytic and antidepressant effects.
    • Inhibition leads to decreased GABA-A receptor modulation, potentially increasing anxiety, depression, and suicidal thoughts.

    2. Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation

    Altered steroid metabolism may dysregulate the HPA axis, increasing cortisol levels, a well-known biomarker of depression and suicidal behavior.

    3. Persistent Epigenetic Changes

    Some animal and human data suggest that finasteride may induce long-lasting changes in gene expression related to stress response and mood regulation, even after discontinuation—supporting the idea of post-finasteride syndrome (PFS).

    4. Neuroinflammation

    Reduced neurosteroids may increase neuroinflammatory signaling, a growing area of interest in the neurobiology of depression and suicidality.

    🧾 Final Thoughts

    The EMA’s announcement is a sobering reminder that drugs affecting hormonal pathways can have wide-reaching systemic effects, including on the brain. With better awareness, screening, and patient education, we can minimize harm and support individuals who may be at risk.

  • Female Physicians at Higher Risk for Suicide: Key Findings

    Female Physicians at Higher Risk for Suicide: Key Findings

    February 26, 2025 study in JAMA Psychiatry reveals alarming trends in physician suicide rates:

    📊 Key Findings

    🔹 Female physicians face a significantly higher suicide risk compared to the general U.S. population.
    🔹 Male physicians have a lower suicide risk than their nonphysician counterparts.

    💡 Why This Matters

    These statistics underscore a deeper systemic issue within healthcare
    ➡️ “Physicians face immense pressure, long hours, and high-stakes decisions, which contribute to burnout and mental health struggles.”

    Failure to address these issues can lead to increased physician turnover, lower quality of care, and worsening healthcare outcomes for patients.

    ✅ What Can Be Done

    ✔️ Reduce stigma around mental health in medical culture.
    ✔️ Implement confidential mental health resources specifically for physicians.
    ✔️ Encourage work-life balance through adjusted schedules and peer support programs.
    ✔️ Offer routine mental health check-ins as part of employee wellness programs.

    📞 Where to Get Help

    🆘 If you or someone you know is struggling, help is available:
    ➡️ Call or text 988 for free, confidential support 24/7.
    ➡️ Visit the Physician Support Line at www.physiciansupportline.com — available 7 days a week with support from licensed psychiatrists.

    💙 It’s time to support those who care for us.

  • 🔍 Suicide & Psychosis: What We Can Learn from Recent Research

    🔍 Suicide & Psychosis: What We Can Learn from Recent Research

    A new study sheds light on suicide risk in patients with psychotic disorders, comparing those with recent-onset schizophrenia or other psychotic disorders to those with longer illness duration. The findings offer critical insights for clinicians and mental health professionals.

    🚨 Key Takeaways:

    📌 Early Illness = Higher Risk: Patients within the first five years of their illness had higher suicide rates, emphasizing the need for intensive early intervention.

    📌 Common Risk Factors: Across both groups, depression, prior suicide attempts, and substance use were major red flags.

    📌 Different Patterns: Those with recent-onset psychosis were more likely to have rapid illness progression, while those with longer illness duration often had chronic distress and social isolation before suicide.

    📌 Missed Opportunities? Many had recent healthcare encounters before suicide, highlighting potential gaps in risk assessment and intervention.

    🛑 What This Means for Us:
    🔹 Early-phase psychosis care should prioritize suicide prevention.
    🔹 Screening for depression, substance use, and prior attempts is essential.
    🔹 More proactive intervention is needed, especially after hospital visits.

    This study reinforces what many frontline clinicians already suspect—suicide prevention in psychosis requires urgent, tailored strategies. How can we improve early detection and support for at-risk patients? Let’s discuss. 👇

  • Breaking Down Barriers: The Impact of Psychotherapy on Suicidal Ideation and Attempts

    Breaking Down Barriers: The Impact of Psychotherapy on Suicidal Ideation and Attempts

    New Insights from JAMA

    This systematic review and meta-analysis dives deep into the impact of both direct and indirect psychotherapy on suicidal ideation and suicide attempts.

    Key takeaways:

    1. Broad Scope: The study analyzed a vast array of data, ensuring a comprehensive overview of psychotherapy’s effectiveness in reducing suicidal thoughts and behaviors.
    2. Direct vs. Indirect Therapy: It highlights the distinct impacts of direct (face-to-face) and indirect (telehealth, self-help) psychotherapeutic approaches.
    3. Hope for Patients: The findings are a beacon of hope, showing significant reductions in suicidal ideation and attempts post-therapy.

    As healthcare providers, this data reinforces the crucial role of psychotherapy in our therapeutic arsenal. It’s a powerful reminder of how our interventions can save lives and offer patients a brighter, more hopeful future.

    For those in psychiatry and mental health care, this is a must-read article that could shape how we approach treatment for individuals at risk.

    Let’s continue to break down barriers and provide life-saving care. 💪✨

    Link to the article: https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2824096

  • 🚨 New Research Alert! 🚨

    🚨 New Research Alert! 🚨

    We’re diving deep into the latest JAMA Psychiatry article on Social Determinants of Health & Suicide-Related Outcomes 🧠💔. This groundbreaking study sheds light on how factors like income, education, and community support play a crucial role in mental health and suicide prevention. 📊🏡💬

    Key Takeaways: 🔍 Social & economic inequalities significantly impact mental well-being. 🛠️ Addressing these factors can save lives and improve outcomes.

    🤝 Community support is more vital than ever.

    💡 With regard to suicide attempt, experience of childhood abuse and maltreatment and sexual assault, gender and sexual minority status, and parental suicide mortality were the strongest risk factors. 

    💡 For suicide mortality, justice system–involved individuals in the community, exposure to others’ and parental suicide, firearm accessibility, divorce, experience in foster care, release from incarceration, and midlife (age 35-65 years) unemployment were the SDOH with consistently strong effects. 

    Join the conversation and let’s work towards a more equitable and supportive world! 🌍✨

    #MentalHealthMatters #JAMAPsychiatry #SocialDeterminants #community #psychiatry #psychiatrist #doctor#mentalhealth #mentalhealthmatters #mentalhealthishealth #SuicidePrevention #HealthEquity #Psychiatry#Research #Wellness 🌈❤️🧠

    🔗 https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2828935

  • The Silent Crisis: Physician Suicide in the United States

    The Silent Crisis: Physician Suicide in the United States

    I saw these magnets today on the refrigerator located in the physicians lounge and it seemed like a good reminder 

    In the U.S., an estimated 300-400 physicians die by suicide each year, a staggering rate far higher than that of the general population. This crisis, largely unspoken in healthcare settings, underscores the immense pressures physicians face daily. The high expectations, long hours, emotional exhaustion, and the stigma around seeking mental health support create a dangerous environment where burnout can quickly spiral into severe mental health struggles.

    Physicians are trained to endure, often putting others’ health before their own. But the costs of “pushing through” take a toll. Many feel they cannot safely reach out for help without risking their careers due to institutional stigma around mental health treatment. This cycle of isolation and suppressed emotion can lead to tragic outcomes.

    Organizations are beginning to address this issue by implementing wellness programs, peer support systems, and confidential mental health resources, but more systemic changes are needed. Reducing the stigma around mental health support, reforming punitive policies, and fostering a culture of openness in medicine could be life-saving.

    Physician suicide affects us all—it robs the healthcare system of dedicated professionals and leaves profound impacts on patients, families, and communities. It’s time to break the silence and actively support those who care for us.

  • Is Clozapine Disease Modifying?

    Is Clozapine Disease Modifying?

    This post comes from my real world experience with treating many patients with treatment resistant schizophrenia. I wanted to create a consolidated post that goes over what we know about the benefits of clozapine in schizophrenia treatment as well as what we do not know. Clozapine is unique among antipsychotics due to its superior efficacy in treatment-resistant schizophrenia (TRS), but whether it is disease-modifying remains debated.

    1. Superior Long-term Outcomes in TRS

    • Reduced Relapse Rates: Clozapine has been shown to reduce relapse rates more effectively than other antipsychotics. For instance, a large cohort study found lower rates of rehospitalization for patients on clozapine compared to those on other second-generation antipsychotics (SGAs). The lower relapse rates may suggest stabilization of disease progression.
    • Cognitive Benefits: Several studies report improvements or stabilization in cognitive function in patients on clozapine, which contrasts with the cognitive decline often observed in schizophrenia. The preservation or improvement in cognitive function could indicate a modification of disease trajectory.

    2. Impact on Mortality and Suicidality

    • Reduced Mortality: Long-term use of clozapine has been associated with lower mortality rates in schizophrenia, both due to reduced suicide risk and fewer overall medical complications compared to other antipsychotics.
    • Suicide Prevention: Clozapine is the only antipsychotic shown to significantly reduce suicidality in schizophrenia patients, which may point to broader effects on disease severity and progression.

    3. Neurobiological Effects

    • Neuroprotection: Preclinical and human imaging studies suggest clozapine might have neuroprotective properties. Some animal models and neuroimaging studies indicate that clozapine can increase neurogenesis, reduce oxidative stress, and potentially protect against the neurodegeneration associated with chronic schizophrenia.
    • Synaptic Remodeling: There is some evidence that clozapine might positively influence synaptic plasticity. Studies suggest it might normalize the synaptic dysfunction seen in schizophrenia, which could theoretically have a disease-modifying effect by restoring some aspects of brain connectivity and function.

    4. Delay in Onset of TRS

    • Intervention Timing: There is emerging evidence suggesting that earlier introduction of clozapine (when TRS is identified) might lead to better long-term functional outcomes. This hints that clozapine could modify the disease course if used earlier in resistant cases, though direct evidence of disease modification remains scarce.

    5. Chronicity and Brain Volume Loss

    • Potential for Reduced Brain Volume Loss: Some studies indicate that clozapine may be associated with less gray matter loss over time compared to other antipsychotics. This could imply a reduction in the neuroprogressive aspects of schizophrenia.

    Limitations in Evidence

    While clozapine shows many positive outcomes, definitive evidence proving it is “disease-modifying” remains elusive:

    • Lack of RCTs Focused on Disease Modification: Most clinical trials focus on symptomatic improvement rather than long-term neurobiological changes or functional outcomes.
    • Challenges in Measuring Disease Progression: Schizophrenia is a complex, heterogeneous disorder with no clear biomarkers for progression, making it difficult to measure whether clozapine alters the underlying disease process.

    In summary, while there is compelling evidence that clozapine leads to better long-term outcomes and may have neuroprotective effects, proving it as a true disease-modifying treatment in schizophrenia requires more robust, long-term studies focused specifically on changes in the disease course.